Savella (milnacipran), FDA approved in 2009

Savella (milnacipran), FDA approved in 2009, is a serotonin norepinephrine reuptake inhibitor (SNRI) used for the management of pain caused by fibromyalgia. Fibromyalgia is a multi-symptom condition, commonly presenting as widespread chronic pain, fatigue and sleep issues. Treatment for fibromyalgia usually involves a combination of drugs (to relieve pain, improve sleep or mood) and non-drug treatments, such as cognitive behavioral therapy, relaxation therapy and aerobic exercise.

NOTE: Although Savella (milnacipran) has been used in the treatment of major depressive disorder and is approved for treating depression in some countries outside the US, this indication is not an FDA-labeled use.

Definitions

\